Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

venBio Select Advisor

Latest statistics and disclosures from Avoro Capital Advisors's latest quarterly 13F-HR filing:

Top 5 stock holdings are UTHR, APLS, ASND, SRPT, MDGL, and represent 34.89% of Avoro Capital Advisors's stock portfolio.
Added to shares of these 10 stocks: VKTX (+$294M), Alpine Immune Sciences (+$229M), VERA (+$227M), ARWR (+$212M), MGNX (+$91M), RNA (+$85M), AUTL (+$79M), IOVA (+$74M), OCUL (+$65M), TSHA (+$41M).
Started 11 new stock positions in MGNX, AUTL, CGON, ADVM, VERA, KYTX, Alpine Immune Sciences, PCVX, VKTX, OCUL. CRSP.
Reduced shares in these 10 stocks: Mirati Therapeutics (-$287M), Cymabay Therapeutics (-$262M), ALNY (-$121M), GPCR (-$95M), Karuna Therapeutics Ord (-$40M), , XBI (-$14M), FENC (-$14M), NUVL (-$13M), KRYS.
Sold out of its positions in Cymabay Therapeutics, FENC, ImmunoGen, Karuna Therapeutics Ord, Mirati Therapeutics, NUVL, GPCR.
Avoro Capital Advisors was a net buyer of stock by $830M.
Avoro Capital Advisors has $8.6B in assets under management (AUM), dropping by 18.42%.
Central Index Key (CIK): 0001633313

Tip: Access up to 7 years of quarterly data

Positions held by venBio Select Advisor consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Avoro Capital Advisors

Avoro Capital Advisors holds 46 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
United Therapeutics Corp Common (UTHR)	7.7	$657M		2.9M	229.72	View chart
Apellis Pharmaceuticals Common (APLS)	7.6	$653M		11M	58.78	View chart
Ascendis Pharma Sponsored ADR (ASND)	7.0	$600M	+5%	4.0M	151.17	View chart
Sarepta Therapeutics Common (SRPT)	6.6	$562M		4.3M	129.46	View chart
Madrigal Pharmaceuticals Common (MDGL)	6.1	$519M	+2%	1.9M	267.04	View chart
Argenx Se Sponsored ADR (ARGX)	5.7	$488M		1.2M	393.72	View chart
Krystal Biotech Common (KRYS)	5.3	$455M		2.6M	177.93	View chart
Spdr Series Trust - S&p Biotech Etf (XBI)	4.8	$408M	-3%	4.3M	94.89	View chart
Biomarin Pharmaceutical Common (BMRN)	4.4	$381M		4.4M	87.34	View chart
Amicus Therapeutics Common (FOLD)	3.8	$323M		27M	11.78	View chart
Cerevel Therapeutics Hldng Common (CERE)	3.7	$319M		7.6M	42.27	View chart
Viking Therapeutics Common (VKTX)	3.4	$294M	NEW	3.6M	82.00	View chart
Arrowhead Pharmaceuticals Common (ARWR)	2.9	$245M	+657%	8.6M	28.60	View chart
Xenon Pharmaceuticals Common (XENE)	2.8	$244M		5.7M	43.05	View chart
Alpine Immune Sciences Common	2.7	$229M	NEW	5.8M	39.64	View chart
Vera Therapeutics Common (VERA)	2.6	$227M	NEW	5.3M	43.12	View chart
Iovance Biotherapeutics Common (IOVA)	2.0	$173M	+74%	12M	14.82	View chart
Intra-cellular Therapies Common (ITCI)	2.0	$171M	+9%	2.5M	69.20	View chart
Kymera Therapeutics Common (KYMR)	1.8	$156M	+3%	3.9M	40.20	View chart
Avidity Biosciences Common (RNA)	1.7	$149M	+132%	5.8M	25.52	View chart
Moonlake Immunotherapeutics Class A Ord (MLTX)	1.5	$130M		2.6M	50.23	View chart
Syndax Pharmaceuticals Common (SNDX)	1.2	$101M		4.2M	23.80	View chart
Macrogenics Common (MGNX)	1.1	$91M	NEW	6.2M	14.72	View chart
Kura Oncology Common (KURA)	1.0	$82M	+29%	3.9M	21.33	View chart
Autolus Therapeutics Sponsored ADR (AUTL)	0.9	$79M	NEW	12M	6.38	View chart
Spyre Therapeutics Common (SYRE)	0.8	$70M		1.8M	37.93	View chart
Soleno Therapeutics Common (SLNO)	0.8	$70M	+107%	1.6M	42.80	View chart
Biocryst Pharmaceuticals Common (BCRX)	0.8	$66M		13M	5.08	View chart
Ocular Therapeutix Common (OCUL)	0.8	$65M	NEW	7.1M	9.10	View chart
Taysha Gene Therapies Common (TSHA)	0.6	$54M	+328%	19M	2.87	View chart
Tourmaline Bio Common (TRML)	0.6	$51M	+155%	2.2M	22.90	View chart
Roivant Sciences Common (ROIV)	0.6	$49M		4.7M	10.54	View chart
Alnylam Pharmaceuticals Common (ALNY)	0.5	$45M	-72%	300k	149.45	View chart
Mannkind Corp Common (MNKD)	0.5	$41M		9.0M	4.53	View chart
Merus N V Common (MRUS)	0.5	$40M		889k	45.03	View chart
Vaxcyte Common (PCVX)	0.5	$39M	NEW	575k	68.31	View chart
Ultragenyx Pharmaceutical Common (RARE)	0.5	$39M	+137%	830k	46.69	View chart
Marinus Pharmaceuticals Common (MRNS)	0.4	$37M	+31%	4.1M	9.04	View chart
Rocket Pharmaceuticals Common (RCKT)	0.4	$34M		1.3M	26.94	View chart
Monte Rosa Therapeutics Common (GLUE)	0.4	$32M		4.5M	7.05	View chart
Cg Oncology Common (CGON)	0.4	$31M	NEW	700k	43.90	View chart
Crispr Therapeutics Common (CRSP)	0.3	$29M	NEW	420k	68.16	View chart
Verrica Pharmaceuticals Common (VRCA)	0.3	$24M		4.0M	5.92	View chart
Kyverna Therapeutics Common (KYTX)	0.1	$12M	NEW	475k	24.84	View chart
Aadi Biosciences Common (AADI)	0.1	$6.7M		2.8M	2.34	View chart
Adverum Biotechnologies Common (ADVM)	0.1	$5.9M	NEW	417k	14.14	View chart

Past Filings by Avoro Capital Advisors

SEC 13F filings are viewable for Avoro Capital Advisors going back to 2014

Avoro Capital Advisors 2024 Q1 filed May 15, 2024
Avoro Capital Advisors 2023 Q4 filed Feb. 14, 2024
Avoro Capital Advisors 2023 Q3 filed Nov. 14, 2023
Avoro Capital Advisors 2023 Q2 filed Aug. 14, 2023
Avoro Capital Advisors 2023 Q1 filed May 15, 2023
Avoro Capital Advisors 2022 Q4 filed Feb. 14, 2023
Avoro Capital Advisors 2022 Q3 filed Nov. 14, 2022
Avoro Capital Advisors 2022 Q2 filed Aug. 15, 2022
Avoro Capital Advisors 2022 Q1 filed May 16, 2022
Avoro Capital Advisors 2021 Q4 filed Feb. 14, 2022
Avoro Capital Advisors 2021 Q3 filed Nov. 15, 2021
Avoro Capital Advisors 2021 Q2 filed Aug. 16, 2021
Avoro Capital Advisors 2021 Q1 filed May 17, 2021
Avoro Capital Advisors 2020 Q4 filed Feb. 16, 2021
Avoro Capital Advisors 2020 Q3 filed Nov. 16, 2020
Avoro Capital Advisors 2020 Q2 filed Aug. 14, 2020

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z